Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;128(5):634-641.
doi: 10.1111/bju.15413. Epub 2021 May 5.

Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response

Patrick J Hensley  1 , Kelly K Bree  1 , Nathan Brooks  1 , Justin Matulay  2 , Roger Li  3 , Graciela M Nogueras González  4 , Neema Navai  1 , Herbert B Grossman  1 , Colin P Dinney  1 , Ashish M Kamat  1
Affiliations

Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response

Patrick J Hensley et al. BJU Int. 2021 Nov.

Abstract

Objectives: To investigate bacille Calmette-Guérin (BCG) tolerability and response with respect to the timing of BCG administration after transurethral resection of bladder tumour (TURBT) in patients with non-muscle-invasive bladder cancer (NMIBC).

Patients and methods: A review of patients with NMIBC at our institution managed with at least 'adequate BCG' (defined by the United States Food and Drug Administration as at least five of six induction instillations, with two additional instillations comprising either maintenance or repeat induction) at our institution from 2000 to 2018 was performed. Time from TURBT to first instillation of induction BCG was stratified by quartile and analysed as a continuous variable. Kaplan-Meier and log-rank tests analysed differences in recurrence-free (RFS) and progression-free survival (PFS). Cox proportional hazards regression models identified associations between risk factors and survival outcomes.

Results: A total of 518 patients received adequate BCG at a median (range) of 26 (6-188) days from TURBT. Overall, 45 patients (9%) developed BCG intolerance at a median (range) 12 (7-33) instillations. When time from TURBT to BCG was stratified into quartiles, there was no difference with respect BCG intolerance (P = 0.966), RFS (P = 0.632) or PFS (P = 0.789). On both uni- and multivariate regression analysis for RFS and PFS, time from TURBT to BCG was not a significant predictor when analysed by quartile or as a continuous variable (the hazard ratio for RFS was 1.00, 95% confidence interval [CI] 0.99-1.00, P = 0.449; and for PFS was 0.99, 95% CI 0.98-1.00, P = 0.074).

Conclusion: The rates of tolerability and response to adequate BCG are not predicated by the timing of induction BCG instillation after TURBT. Early administration in properly selected patients is safe and delays do not affect therapeutic response.

Keywords: #BladderCancer; #blcsm; #uroonc; BCG-unresponsive; bacille Calmette-Guérin; bladder cancer; intravesical therapy; transurethral resection of bladder tumour.

PubMed Disclaimer

References

    1. Babjuk M, Burger M, Compérat EM et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol 2019; 76: 639-57
    1. Chang SS, Boorjian SA, Chou R et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 2016; 196: 1021-9
    1. Boehm BE, Cornell JE, Wang H, Mukherjee N, Oppenheimer JS, Svatek RS. Efficacy of bacillus Calmette-Guérin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol 2017; 198: 503-10
    1. Oddens J, Brausi M, Sylvester R et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013; 63: 462-72
    1. Martínez-Piñeiro L, Portillo JA, Fernández JM et al. Maintenance therapy with 3-monthly bacillus Calmette-Guérin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol 2015; 68: 256-62

Publication types

LinkOut - more resources